Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

<b>Background/Objectives:</b> The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by an enriched stroma, hampering the effectiveness of therapy. This co-clinical study aimed to (1) provide insight into early post-treatment changes in the TME using multiparametric magnetic resonance imaging (mpMRI)-derived quantitative imaging biomarkers (QIBs) in a preclinical PDAC model treated with radiotherapy and correlate these QIBs with histology; (2) evaluate the feasibility of obtaining these QIBs in patients with PDAC using clinically approved mpMRI data acquisitions. <b>Methods</b>: Athymic mice (<i>n</i> = 12) at pre- and post-treatment as well as patients with PDAC (n = 11) at pre-treatment underwent mpMRI including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) data acquisition sequences. DW and DCE data were analyzed using monoexponential and extended Tofts models, respectively. DeepLIIF quantified the total percentage (%) of tumor cells in hematoxylin and eosin (H&E)-stained tissues from athymic mice. Spearman correlation and Wilcoxon signed rank tests were performed for statistical analysis. <b>Results</b>: In the preclinical PDAC model, mean pre- and post-treatment ADC and K<sup>trans</sup> values differed significantly (<i>p</i> < 0.01), changing by 20.50% and 20.41%, respectively, and the median total tumor cells quantified by DeepLIIF was 24% (range: 15-53%). Post-treatment ADC values and relative change in v<sub>e</sub> (rΔv<sub>e</sub>) showed a significant negative correlation with total tumor cells (<i>ρ</i> = -0.77, <i>p</i> < 0.014 for ADC and <i>ρ</i> = -0.77, <i>p</i> = 0.009 for rΔv<sub>e</sub>). In patients with PDAC, pre-treatment mean ADC and K<sup>trans</sup> values were 1.76 × 10<sup>-3</sup> (mm<sup>2</sup>/s) and 0.24 (min<sup>-1</sup>), respectively. <b>Conclusions</b>: QIBs in both preclinical and clinical settings underscore their potential for future co-clinical research to evaluate emerging drug combinations targeting both tumor and stroma.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-01-15
DOI
https://doi.org/10.3390/cancers18020273
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

Muhammad Awais, Ramesh Paudyal, Joseph O. Deasy, James Russell et al.
Cancers
Pancreatic and Hepatic Oncology Research
article

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

Muhammad Awais, Ramesh Paudyal, Joseph O. Deasy, James Russell, John L. Humm, Lauren Schwartz, Richard K. G. Do, H. Carl Lekaye, Amita Shukla-Dave, Saad Nadeem
article en

Abstract

<b>Background/Objectives:</b> The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by an enriched stroma, hampering the effectiveness of therapy. This co-clinical study aimed to (1) provide insight into early post-treatment changes in the TME using multiparametric magnetic resonance imaging (mpMRI)-derived quantitative imaging biomarkers (QIBs) in a preclinical PDAC model treated with radiotherapy and correlate these QIBs with histology; (2) evaluate the feasibility of obtaining these QIBs in patients with PDAC using clinically approved mpMRI data acquisitions. <b>Methods</b>: Athymic mice (<i>n</i> = 12) at pre- and post-treatment as well as patients with PDAC (n = 11) at pre-treatment underwent mpMRI including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) data acquisition sequences. DW and DCE data were analyzed using monoexponential and extended Tofts models, respectively. DeepLIIF quantified the total percentage (%) of tumor cells in hematoxylin and eosin (H&E)-stained tissues from athymic mice. Spearman correlation and Wilcoxon signed rank tests were performed for statistical analysis. <b>Results</b>: In the preclinical PDAC model, mean pre- and post-treatment ADC and K<sup>trans</sup> values differed significantly (<i>p</i> < 0.01), changing by 20.50% and 20.41%, respectively, and the median total tumor cells quantified by DeepLIIF was 24% (range: 15-53%). Post-treatment ADC values and relative change in v<sub>e</sub> (rΔv<sub>e</sub>) showed a significant negative correlation with total tumor cells (<i>ρ</i> = -0.77, <i>p</i> < 0.014 for ADC and <i>ρ</i> = -0.77, <i>p</i> = 0.009 for rΔv<sub>e</sub>). In patients with PDAC, pre-treatment mean ADC and K<sup>trans</sup> values were 1.76 × 10<sup>-3</sup> (mm<sup>2</sup>/s) and 0.24 (min<sup>-1</sup>), respectively. <b>Conclusions</b>: QIBs in both preclinical and clinical settings underscore their potential for future co-clinical research to evaluate emerging drug combinations targeting both tumor and stroma.

CancersVol. 18(2)
Memorial Sloan Kettering Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 86%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.